U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices

About this resource:

Non-Systematic Review

Source: Centers for Disease Control and Prevention

Last Reviewed: March 2015

Workgroups: Immunization and Infectious Diseases Workgroup

This report updates the Advisory Committee on Immunization Practices’ (ACIP) recommendation for human papillomavirus (HPV) vaccination to include the 9-valent HPV vaccine (9vHPV) as 1 of 3 available for routine vaccination, along with the 2-valent and 4-valent HPV vaccines. 9vHPV offers protection against 9 different types of HPV.

ACIP recommends:

  • 9vHPV, 4vHPV, or 2vHPV for routine vaccination of females age 11 or 12 years and females through age 26 years who haven’t been vaccinated previously, or who haven’t completed the 3-dose series
  • 9vHPV or 4vHPV for routine vaccination of males age 11 or 12 years and males through age 21 years who haven’t been vaccinated previously, or who haven’t completed the 3-dose series
  • 9vHPV or 4vHPV to vaccinate men who have sex with men and immunocompromised people (including those with HIV infection) through age 26 years, if not vaccinated previously
Read more about this resource

Objectives related to this resource (2)

Increase the proportion of adolescents who get recommended doses of the HPV vaccine — IID‑08
Improving
Reduce infections of HPV types prevented by the vaccine in young adults — IID‑07
Baseline only

Suggested Citation

1.

Petrosky E, Bocchini JA, Hariri S, et al. (2015). Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. Retrieved from https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm.